Eradivir Phase 2 study of EV25 (IMAGE)
Caption
Two Eradivir employees conduct research on the company’s EV25 influenza therapeutic. Eradivir, a clinical stage biotech company, will begin a Phase 2 challenge study with its antiviral therapeutic, EV25.
Credit
(Eradivir photo/Gregory Eakins)
Usage Restrictions
None
License
Original content